Literature DB >> 19760257

Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis.

Janine Kirby1, Emily F Goodall, William Smith, J Robin Highley, Rudo Masanzu, Judith A Hartley, Rachel Hibberd, Hannah C Hollinger, Stephen B Wharton, Karen E Morrison, Paul G Ince, Christopher J McDermott, Pamela J Shaw.   

Abstract

The finding of TDP-43 as a major component of ubiquitinated protein inclusions in amyotrophic lateral sclerosis (ALS) has led to the identification of 30 mutations in the transactive response-DNA binding protein (TARDBP) gene, encoding TDP-43. All but one are in exon 6, which encodes the glycine-rich domain. The aim of this study was to determine the frequency of TARDBP mutations in a large cohort of motor neurone disease patients from Northern England (42 non-superoxide dismutase 1 (SOD1) familial ALS (FALS), nine ALS-frontotemporal dementia, 474 sporadic ALS (SALS), 45 progressive muscular atrophy cases). We identified four mutations, two of which were novel, in two familial (FALS) and two sporadic (SALS) cases, giving a frequency of TARDBP mutations in non-SOD1 FALS of 5% and SALS of 0.4%. Analysis of clinical data identified that patients had typical ALS, with limb or bulbar onset, and showed considerable variation in age of onset and rapidity of disease course. However, all cases had an absence of clinically overt cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760257     DOI: 10.1007/s10048-009-0218-9

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  35 in total

1.  The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study.

Authors:  J J Kew; L H Goldstein; P N Leigh; S Abrahams; N Cosgrave; R E Passingham; R S Frackowiak; D J Brooks
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

2.  TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration.

Authors:  Lina Benajiba; Isabelle Le Ber; Agnès Camuzat; Mathieu Lacoste; Catherine Thomas-Anterion; Philippe Couratier; Solenn Legallic; François Salachas; Didier Hannequin; Marielle Decousus; Lucette Lacomblez; Eric Guedj; Véronique Golfier; William Camu; Bruno Dubois; Dominique Campion; Vincent Meininger; Alexis Brice
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

3.  TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.

Authors:  Michael J Strong; Kathryn Volkening; Robert Hammond; Wencheng Yang; Wendy Strong; Cheryl Leystra-Lantz; Christen Shoesmith
Journal:  Mol Cell Neurosci       Date:  2007-03-20       Impact factor: 4.314

4.  Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Authors:  Ian R A Mackenzie; Eileen H Bigio; Paul G Ince; Felix Geser; Manuela Neumann; Nigel J Cairns; Linda K Kwong; Mark S Forman; John Ravits; Heather Stewart; Andrew Eisen; Leo McClusky; Hans A Kretzschmar; Camelia M Monoranu; J Robin Highley; Janine Kirby; Teepu Siddique; Pamela J Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

5.  TDP-43 mutation in familial amyotrophic lateral sclerosis.

Authors:  Akio Yokoseki; Atsushi Shiga; Chun-Feng Tan; Asako Tagawa; Hiroyuki Kaneko; Akihide Koyama; Hiroto Eguchi; Akira Tsujino; Takeshi Ikeuchi; Akiyoshi Kakita; Koichi Okamoto; Masatoyo Nishizawa; Hitoshi Takahashi; Osamu Onodera
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

Review 6.  Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene.

Authors:  Peter M Andersen
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

7.  TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing.

Authors:  Emanuele Buratti; Antonia Brindisi; Maurizio Giombi; Sergio Tisminetzky; Youhna M Ayala; Francisco E Baralle
Journal:  J Biol Chem       Date:  2005-09-12       Impact factor: 5.157

8.  Structural determinants of the cellular localization and shuttling of TDP-43.

Authors:  Youhna M Ayala; Paola Zago; Andrea D'Ambrogio; Ya-Fei Xu; Leonard Petrucelli; Emanuele Buratti; Francisco E Baralle
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

9.  Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.

Authors:  E Buratti; T Dörk; E Zuccato; F Pagani; M Romano; F E Baralle
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

10.  Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3.

Authors:  Caroline Vance; Ammar Al-Chalabi; Deborah Ruddy; Bradley N Smith; Xun Hu; Jemeen Sreedharan; Teepu Siddique; H Jurgen Schelhaas; Benno Kusters; Dirk Troost; Frank Baas; Vianney de Jong; Christopher E Shaw
Journal:  Brain       Date:  2006-02-22       Impact factor: 13.501

View more
  30 in total

Review 1.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

Review 2.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

3.  Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene.

Authors:  Adriano Chiò; Giuseppe Borghero; Maura Pugliatti; Anna Ticca; Andrea Calvo; Cristina Moglia; Roberto Mutani; Maura Brunetti; Irene Ossola; Maria Giovanna Marrosu; Maria Rita Murru; Gianluca Floris; Antonino Cannas; Leslie D Parish; Paola Cossu; Yevgeniya Abramzon; Janel O Johnson; Michael A Nalls; Sampath Arepalli; Sean Chong; Dena G Hernandez; Bryan J Traynor; Gabriella Restagno
Journal:  Arch Neurol       Date:  2011-01-10

Review 4.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

Review 5.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 6.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

7.  Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.

Authors:  Jianlan Gu; Feng Chen; Khalid Iqbal; Cheng-Xin Gong; Xinglong Wang; Fei Liu
Journal:  J Biol Chem       Date:  2017-05-09       Impact factor: 5.157

Review 8.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

9.  Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization.

Authors:  Wenzhang Wang; Hiroyuki Arakawa; Luwen Wang; Ogoegbunam Okolo; Sandra L Siedlak; Yinfei Jiang; Ju Gao; Fei Xie; Robert B Petersen; Xinglong Wang
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

Review 10.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.